Biodesix will announce Q1 2025 financial results on May 13, followed by a conference call and webcast.
Quiver AI Summary
Biodesix, Inc. announced that it will release its financial results for the first quarter ending March 31, 2025, on May 13, with a conference call and webcast scheduled for 4:30 p.m. Eastern Time the same day to discuss the results and company updates. Interested listeners can register for the webcast, and analysts can participate in a question-and-answer session. A recording of the webcast will be available on the company's investor website shortly after its conclusion. Biodesix specializes in diagnostic solutions to enhance patient care for those with lung disease, and this press release contains forward-looking statements that are subject to risks and uncertainties. For more information, Biodesix's trademarks include Nodify Lung and IQLung, and further details can be found on their website.
Potential Positives
- Biodesix will soon release its financial results for the first quarter of 2025, providing transparency and insights into the company's performance.
- The scheduled conference call and webcast allows stakeholders to engage directly with management, enhancing communication and shareholder relations.
- Biodesix continues to innovate in the diagnostic solutions space with its products like Nodify Lung® and IQLung™, which support personalized patient care in lung disease.
Potential Negatives
- The press release includes a significant disclaimer regarding forward-looking statements, highlighting potential risks and uncertainties that could materially affect the company's future performance and results.
- There is an implied concern regarding the company's ability to continue as a going concern, which may signal to investors that there could be financial challenges ahead.
- The mention of various factors that could negatively impact projections, including the effects of the COVID-19 pandemic, could create uncertainty around the company's future revenue and growth potential.
FAQ
When will Biodesix release its first quarter financial results?
Biodesix will release its financial results for the first quarter on May 13, 2025.
What time is the Biodesix conference call on May 13?
The conference call will take place at 4:30 p.m. Eastern Time on May 13, 2025.
How can I access the Biodesix webcast?
Listeners can register for the webcast through the link provided in the press release.
Where can I find the replay of the Biodesix conference call?
A replay of the webcast will be available on Biodesix’s investor website approximately two hours after the call concludes.
What diagnostic solutions does Biodesix offer?
Biodesix offers diagnostic tests like Nodify Lung® and IQLung™ for lung disease management and treatment guidance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDSX Insider Trading Activity
$BDSX insiders have traded $BDSX stock on the open market 25 times in the past 6 months. Of those trades, 10 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $BDSX stock by insiders over the last 6 months:
- JACK W SCHULER has made 3 purchases buying 400,253 shares for an estimated $493,424 and 0 sales.
- LAWRENCE T. JR KENNEDY has made 3 purchases buying 106,200 shares for an estimated $137,629 and 0 sales.
- JOHN PATIENCE purchased 75,000 shares for an estimated $103,710
- SCOTT HUTTON (President & CEO) has made 0 purchases and 3 sales selling 87,400 shares for an estimated $82,538.
- MATTHEW STROBECK has made 2 purchases buying 40,000 shares for an estimated $55,915 and 0 sales.
- HANY MASSARANY purchased 22,500 shares for an estimated $30,865
- ROBIN HARPER COWIE (CFO, Sec'y & Treasurer) has made 0 purchases and 3 sales selling 25,635 shares for an estimated $24,149.
- KIERAN O'KANE (Chief Commercial Officer) has made 0 purchases and 3 sales selling 17,989 shares for an estimated $16,843.
- GARY ANTHONY PESTANO (Chief Development Officer) has made 0 purchases and 3 sales selling 17,175 shares for an estimated $16,074.
- CHRIS VAZQUEZ (Chief Accounting Officer) has made 0 purchases and 3 sales selling 3,833 shares for an estimated $3,638.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BDSX Hedge Fund Activity
We have seen 39 institutional investors add shares of $BDSX stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIO CAPITAL MANAGEMENT, LLC removed 4,338,514 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,637,926
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 4,038,065 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,178,239
- SAMJO MANAGEMENT, LLC added 2,477,400 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,790,422
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 987,475 shares (+769.8%) to their portfolio in Q4 2024, for an estimated $1,510,836
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 971,197 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,485,931
- VANGUARD GROUP INC added 861,000 shares (+29.1%) to their portfolio in Q4 2024, for an estimated $1,317,330
- FARALLON CAPITAL MANAGEMENT LLC removed 825,365 shares (-17.8%) from their portfolio in Q4 2024, for an estimated $1,262,808
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Listeners can register for the webcast via this link . Analysts who wish to participate in the question and answer session should use this link . A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Diagnostic Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com .
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024 or subsequent quarterly reports on Form 10-Q during 2024, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Media:
Natalie St. Denis
[email protected]
(720) 925-9285
Investors:
Chris Brinzey
[email protected]
(339) 970-2843
